Anavex Q2 2024 Earnings Report

Reported financial results for the fiscal quarter ended March 31, 2024.

Key Takeaways

Anavex Life Sciences reported its financial results for the fiscal quarter ended March 31, 2024, and provided a business update. The company is encouraged by the FDA guidance for Early Alzheimer’s disease and the progress of the Marketing Authorisation application to the European Medicines Agency (EMA) for blarcamesine related to the treatment of Alzheimer’s disease.

FDA guidance for Early Alzheimer’s disease states that one cognitive measurement alone, like ADAS-Cog13, could be a sufficient primary endpoint.

Marketing Authorisation application to the European Medicines Agency (EMA) for blarcamesine related to the treatment of Alzheimer’s disease is underway.

First cohort of schizophrenia patients in the ongoing ANAVEX®3-71-SZ-001 Phase 2 trial of ANAVEX®3-71 has been fully enrolled.

Committed to the development of programs within neurodegenerative and neurodevelopmental disorders.

Previous year: -$0.17

-23.5%

General and administrative expenses

$2.9M

Research and development expenses

$9.7M